Appropriateness of Angioplasty in Patients With Chronic Coronary Syndromes

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of Sao Paulo General Hospital

About this trial

Percutaneous coronary intervention (PCI) has dramatically changed the treatment of obstructive coronary artery disease patients. PCI is indicated in patients with chronic coronary syndrome (CCS) symptoms unresponsive to optimized medical therapy. The American College of Cardiology Foundation and partners developed in 2009 - and updated them in May 2017 - the appropriateness criteria for PCI to support the rational use of PCI in chronic patients and to provide patients with high-quality cardiovascular care. Since then, these criteria have been applied to guide physicians and serve as metrics of the quality of care based on the best available scientific evidence. Countries like the United States and Japan already have robust studies on the topic with important repercussions on clinical practice. In Brazil, to date, there are no studies on the adequacy of PCIs in patients with CCS.

Eligibility criteria

Qualifiers

All patients within the age range who underwent elective PCI defined as a procedure indicated in an outpatient scenario or an inpatient in a non-acute setting when the Heart Team was called to evaluate the patient and agreed with the indication for PCI

Disqualifiers

History of acute coronary syndrome < 30 days of the referral for PCI

Trial design

Treatments tested in this trial

  • Percutaneous Coronary Intervention (PCI)

Treatment groups

1,875 Participants
are divided into 1 treatment group

Sponsors and collaborators

University of Sao Paulo General Hospital

Lead sponsor

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.

Collaborator